Adeno-associated virus (AAV)-mediated delivery holds promise for DMD therapy, supported by precedents in other diseases where AAV vectors delivered lncRNAs like H19 (cancer), Malat1 (vascular disease), and Neat1 (neurological disorders) to achieve therapeutic effects. This evidence concerns the gene NEAT1 and Duchenne muscular dystrophy.